Overview

Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days following confirmation of a COVID-19 infection.

Phase:

Phase 2

Details

Lead Sponsor:

Institut de Recherches Cliniques de Montreal

Collaborators:

Pharmascience Inc.
Quercis Pharma AG
SCiAN Services, Inc.